期刊文献+

雌激素受体表达与癌家族史阳性乳腺癌的关系 被引量:4

Relationship between expression of estrogen receptor and breast cancer with a positive cancerous family history
暂未订购
导出
摘要 目的 为了探讨癌家族史阳性乳腺癌妇女ER水平是否高于非癌家族性乳腺癌者。方法 采用莹光组织化学法检测了本院 1985~ 1998年间 430例妇女可手术乳腺癌的新鲜组织ER水平 ,对其中癌家族史阳性乳腺癌ER与非癌家族性乳腺癌ER水平进行比较分析。结果 在 430例乳腺癌组织总的ER阳性率为 5 0 .2 % (2 16 / 430 ) ,其中绝经期前、后ER阳性率分别为 46 .3 % (6 8/ 14 7)和 5 0 .7% (10 7/ 2 11)。癌家族史阳性乳腺癌ER阳性率为 5 5 .1% (2 7/ 49) ;家族性乳腺癌ER阳性率为 72 .2 % (8/ 11) ;非癌家族性乳腺癌ER阳性率为 49.6 % (189/ 381)。结论 癌家族史阳性乳腺癌ER和家族性乳腺癌ER水平分别与非癌家族性乳腺癌ER相比 ,各呈明显增高倾向 ,但经统计学处理P >0 .0 5 ,认为无显著差异。本组乳腺癌病人中至少半数病例属于雌激素受体依赖性肿瘤 ,而且绝经期后水平略高于绝经期前者。 Objective To explore whether ER level of breast cancer with a positive cancerous family history shows a higher level than the breast cancer of non cancerous family.Methods ER were determined in 430 fresh specimen of breast cancer by fluorescent estradiol histochemical technique.Results Total ER positive rate was 50.2%,ER positive rate was 55.1% in the breast cancer with a positive cancerous family history.ER positive rate was 72.2% in women with a family history of breast cancer and ER positive rate was 49.6% in non cancerous family women.Conclusions ER level in breast cancer with a positive cancerous history and family history of breast cancer is significant higher than that in the breast cancer of non cancerous family without statistical difference(P>0.05). [
作者 石小毅 沈明
出处 《中国肿瘤临床与康复》 2000年第5期14-15,共2页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 家族性乳腺癌 雌激素受体 癌家族史 cancerous family history estrogen receptor family breast cancer
  • 相关文献

参考文献2

  • 1阚秀 赵蕊 等.国人与美、日等国妇女乳腺癌的临床病理对比[J].中国肿瘤临床,1987,14:262-5.
  • 2野水整 柿沼雄二 等.癌家族历上乳癌.第四届日本乳癌学会总会论文摘要[M].,1996,6(26)..

同被引文献39

  • 1马擘,宁连胜,史玉荣.乳腺癌家族史对乳腺癌临床特点及预后的影响[J].中华肿瘤防治杂志,2006,13(3):173-176. 被引量:10
  • 2[1]Anonymous. Breast cancer and hormone replacement therapy: col-laborative reanalysis of data from 51 epidemiological studies of 52, 705 wonen with breast camcer and 108, 411 women without breast cancer Collaborative Group on Hormonal Factors in Breast Can-cer.1977, 350(9084):1047-59
  • 3[2]Writing group for the women's Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the women's Health Initiative ran-domized controlled trial.JAMA,2002,288(3): 32-33
  • 4[3]Schairer C, Lubin J., Troisi R, et al. Menopausal estrogen and es tro-progestin replacement therapy and breast cancer risk .JAMA, 2002,283:485-91
  • 5[5]Lavecchia, C; Negri,E; Franceschi,S; et al.Hormone replacement treatment and breast cancer risk: a cooperative Italian study.Br J Cancer, 1995,72: 244-8
  • 6[6]Chen, C L; Weiss, N S; Newcomb, P; et al. Hormone replacement therapy in relation to breast cancer. JAMA, 2002,287:734-41
  • 7[7]Li, C L; Weiss, N S; Stanford, J L; et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer, 2000, 88:2570-7
  • 8[8]Li cl; Malone, K E; Porter, P L; et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA, 2003,289:3254-63
  • 9[9]Stahlberg C, Pedersen AT, Lynge E, et al. Hormone replacement therapy and risk of breast Cancer: the role of progestins. Acta Ob stet Gynecol Scand, 2003,82:335-44
  • 10Mohammed S N,Smith P,Hodgson S N,et al.Family history and survival in premenopausal breast cancer[J].BrJ Cancer,1998,77(12):2252-2256.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部